{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:14:54Z","timestamp":1769170494911,"version":"3.49.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:54:24Z","timestamp":1747929264000},"page":"534-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomic profiling of urological malignancies using tissue-based next generation sequencing"],"prefix":"10.1016","volume":"43","author":[{"given":"Zainab I.","family":"Alruwaii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamze","family":"Gokturk Ozcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oudai","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-8751","authenticated-orcid":false,"given":"Khaleel I.","family":"Al-Obaidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0001","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","article-title":"The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges","volume":"136","author":"Mohanty","year":"2023","journal-title":"Hum Pathol"},{"issue":"31","key":"10.1016\/j.urolonc.2025.04.011_bib0003","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016684","article-title":"incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: a SEER-based analysis","volume":"98","author":"Feng","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"7456","key":"10.1016\/j.urolonc.2025.04.011_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Cancer Genome Atlas Research N. comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/his.14641","article-title":"The pathological and molecular genetic landscape of the hereditary renal cancer predisposition syndromes","volume":"81","author":"Al-Obaidy","year":"2022","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.urolonc.2025.04.011_bib0006","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.18632\/oncotarget.14704","article-title":"Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.urolonc.2025.04.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026930","article-title":"The many roles of BAF (mSWI\/SNF) and PBAF complexes in cancer","volume":"6","author":"Hodges","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.011_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","article-title":"Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"issue":"7331","key":"10.1016\/j.urolonc.2025.04.011_bib0009","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/modpathol.2015.123","article-title":"Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death","volume":"29","author":"Ho","year":"2016","journal-title":"Mod Pathol"},{"issue":"14","key":"10.1016\/j.urolonc.2025.04.011_bib0011","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/0008-5472.CAN-13-0360","article-title":"Cooperation and antagonism among cancer genes: the renal cancer paradigm","volume":"73","author":"Pena-Llopis","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.urolonc.2025.04.011_bib0013","doi-asserted-by":"crossref","first-page":"820","DOI":"10.6004\/jnccn.2016.0086","article-title":"Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma","volume":"14","author":"Fay","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0014","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euf.2015.11.007","article-title":"Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response","volume":"2","author":"Ho","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"6377","key":"10.1016\/j.urolonc.2025.04.011_bib0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0016","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/gcc.22116","article-title":"Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma","volume":"53","author":"Gossage","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2025.04.011_bib0017","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas","year":"2013","journal-title":"Cancer J"},{"issue":"10","key":"10.1016\/j.urolonc.2025.04.011_bib0019","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.critrevonc.2015.05.008","article-title":"Papillary renal cell carcinoma: a review of the current therapeutic landscape","volume":"96","author":"Courthod","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0021","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PAP.0000000000000220","article-title":"Papillary renal cell carcinoma (PRCC): an Update","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv Anat Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.011_bib0022","first-page":"537","article-title":"Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors","volume":"10","author":"Delahunt","year":"1997","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0023","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0024","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.011_bib0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41379-020-0645-6","article-title":"MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features","volume":"34","author":"Denize","year":"2021","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.011_bib0026","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41379-019-0362-1","article-title":"Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity","volume":"33","author":"Al-Obaidy","year":"2020","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0027","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.04.011_bib0028","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/PAS.0000000000000247","article-title":"The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features","volume":"38","author":"Chevarie-Davis","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0029","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Schoffski","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.011_bib0032","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/430842","article-title":"Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome","volume":"76","author":"Schmidt","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.011_bib0033","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.urolonc.2025.04.011_bib0034","doi-asserted-by":"crossref","first-page":"e92688","DOI":"10.1172\/jci.insight.92688","article-title":"Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma","volume":"2","author":"Casuscelli","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0035","first-page":"356","article-title":"Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization","volume":"145","author":"Speicher","year":"1994","journal-title":"Am J Pathol"},{"issue":"13","key":"10.1016\/j.urolonc.2025.04.011_bib0036","first-page":"2927","article-title":"Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma","volume":"56","author":"Schwerdtle","year":"1996","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0037","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/modpathol.3800286","article-title":"Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma","volume":"18","author":"Brunelli","year":"2005","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.04.011_bib0038","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.celrep.2015.10.059","article-title":"The genomic landscape of renal oncocytoma identifies a metabolic barrier to tumorigenesis","volume":"13","author":"Joshi","year":"2015","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.011_bib0039","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0040","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0041","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-018-2438-9","article-title":"ICUD-SIU International Consultation on bladder cancer 2017: management of non-muscle invasive bladder cancer","volume":"37","author":"Monteiro","year":"2019","journal-title":"World J Urol"},{"issue":"7457","key":"10.1016\/j.urolonc.2025.04.011_bib0042","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"7484","key":"10.1016\/j.urolonc.2025.04.011_bib0043","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"7492","key":"10.1016\/j.urolonc.2025.04.011_bib0044","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0045","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"issue":"10031","key":"10.1016\/j.urolonc.2025.04.011_bib0046","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0047","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"issue":"25","key":"10.1016\/j.urolonc.2025.04.011_bib0048","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.urolonc.2025.04.011_bib0049","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102643","article-title":"Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study","volume":"53","author":"Hosen","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.011_bib0051","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0052","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2353\/ajpath.2010.100354","article-title":"Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer","volume":"177","author":"Tomlinson","year":"2010","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0053","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.2892","article-title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma","volume":"224","author":"HA","year":"2011","journal-title":"J Pathol"},{"issue":"20","key":"10.1016\/j.urolonc.2025.04.011_bib0054","doi-asserted-by":"crossref","first-page":"12659","DOI":"10.3390\/ijms232012659","article-title":"Her-2 Targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates","volume":"23","author":"Albarran","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0055","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.011_bib0056","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers12061550","article-title":"Clinical applications of molecular biomarkers in prostate cancer","volume":"12","author":"Cou\u00f1ago","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0057","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0058","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.urolonc.2025.04.011_bib0059","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11912-018-0707-9","article-title":"Molecular subtypes of prostate cancer","volume":"20","author":"Arora","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"17-18","key":"10.1016\/j.urolonc.2025.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0061","article-title":"Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration","author":"Zengin","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0062","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0063","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-20-2371","article-title":"Characterizing CDK12-mutated prostate cancers","volume":"27","author":"Rescigno","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.urolonc.2025.04.011_bib0064","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1158\/1078-0432.CCR-23-1439","article-title":"SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression","volume":"29","author":"Geng","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0065","doi-asserted-by":"crossref","first-page":"e001065","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.urolonc.2025.04.011_bib0066","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: philadelphia prostate cancer consensus conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0067","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2019.09.013","article-title":"Morphology, p16, HPV, and outcomes in squamous cell carcinoma of the penis: a multi-institutional study","volume":"96","author":"Eich","year":"2020","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0068","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","article-title":"Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis","volume":"20","author":"Olesen","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0069","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00428-019-02607-8","article-title":"The molecular pathogenesis of penile carcinoma-current developments and understanding","volume":"475","author":"Emmanuel","year":"2019","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.urolonc.2025.04.011_bib0070","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-20-4004","article-title":"Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma","volume":"27","author":"Chahoud","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.urolonc.2025.04.011_bib0071","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.urolonc.2025.04.011_bib0072","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer\u2013discoveries and updates","volume":"371","author":"Hanna","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.urolonc.2025.04.011_bib0073","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41568-019-0178-9","article-title":"Human germ cell tumours from a developmental perspective","volume":"19","author":"Oosterhuis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0074","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1038\/ncomms6973","article-title":"Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours","volume":"6","author":"Litchfield","year":"2015","journal-title":"Nat Commun"},{"issue":"7631","key":"10.1016\/j.urolonc.2025.04.011_bib0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature20596","article-title":"Genomic evolution and chemoresistance in germ-cell tumours","volume":"540","author":"Taylor-Weiner","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0076","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14737140.2020.1717337","article-title":"Molecular characteristics of testicular germ cell tumors: pathogenesis and mechanisms of therapy resistance","volume":"20","author":"Al-Obaidy","year":"2020","journal-title":"Expert Rev Anticanc Ther"},{"issue":"9","key":"10.1016\/j.urolonc.2025.04.011_bib0077","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/humrep\/deaa150","article-title":"WNT signalling in the normal human adult testis and in male germ cell neoplasms","volume":"35","author":"Young","year":"2020","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0078","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41467-023-38378-9","article-title":"Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence","volume":"14","author":"Xu","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.urolonc.2025.04.011_bib0079","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.celrep.2018.05.039","article-title":"Integrated molecular characterization of testicular germ cell tumors","volume":"23","author":"Shen","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087444","article-title":"Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells","volume":"9","author":"Abada","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.011_bib0081","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/cc.4.6.1742","article-title":"ATM activation in normal human tissues and testicular cancer","volume":"4","author":"Bartkova","year":"2005","journal-title":"Cell Cycle"},{"issue":"7035","key":"10.1016\/j.urolonc.2025.04.011_bib0082","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0083","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-018-0029-0","article-title":"Testicular cancer","volume":"4","author":"Cheng","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0084","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3389\/fonc.2018.00571","article-title":"Emerging prognostic biomarkers in testicular germ cell tumors: looking beyond established practice","volume":"8","author":"Chovanec","year":"2018","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.011_bib0085","first-page":"585","article-title":"Leydig cell tumors of the testis: a molecular-cytogenetic study based on a large series of patients","volume":"17","author":"Verdorfer","year":"2007","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0086","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/his.15175","article-title":"\u03b2-Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis","volume":"85","author":"Kitagawa","year":"2024","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.urolonc.2025.04.011_bib0087","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1210\/jc.2006-0183","article-title":"Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations","volume":"91","author":"Carvajal-Carmona","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.urolonc.2025.04.011_bib0088","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJM199912023412304","article-title":"Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor","volume":"341","author":"Liu","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0089","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2164\/jandrol.111.013441","article-title":"A rare cause of hypertestosteronemia in a 68-year-old patient: a Leydig cell tumor due to a somatic GNAS (guanine nucleotide-binding protein, alpha-stimulating activity polypeptide 1)-activating mutation","volume":"33","author":"Lib\u00e9","year":"2012","journal-title":"J Androl"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0090","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euf.2019.05.012","article-title":"Genomic features of metastatic testicular sex cord stromal tumors","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.011_bib0091","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/his.14225","article-title":"The leydig cell tumour scaled score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification","volume":"78","author":"Colecchia","year":"2021","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.urolonc.2025.04.011_bib0092","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s41379-021-00845-3","article-title":"Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features","volume":"34","author":"Rizzo","year":"2021","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0093","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00428-007-0385-8","article-title":"Molecular-cytogenetic characterisation of sex cord-stromal tumours: CGH analysis in sertoli cell tumours of the testis","volume":"450","author":"Verdorfer","year":"2007","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.011_bib0094","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/PAS.0b013e31829cdbc6","article-title":"Colecchia M. frequent mutation and nuclear localization of \u03b2-catenin in sertoli cell tumors of the testis","volume":"38","author":"Perrone","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00428-017-2090-6","article-title":"The role of beta-catenin mutation and SOX9 expression in sex cord-stromal tumours of the testis","volume":"470","author":"Bremmer","year":"2017","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.011_bib0096","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/PAS.0000000000001849","article-title":"Large cell calcifying sertoli cell tumor: a clinicopathologic study of 18 cases with comprehensive review of the literature and reappraisal of prognostic features","volume":"46","author":"Al-Obaidy","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.04.011_bib0097","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/js.2019-00022","article-title":"Somatic PRKAR1A gene mutation in a nonsyndromic metastatic large cell calcifying sertoli cell tumor","volume":"3","author":"Tatsi","year":"2019","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.011_bib0098","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MOP.0b013e328355a279","article-title":"Large-cell calcifying Sertoli cell tumors of the testes in pediatrics","volume":"24","author":"Gourgari","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.urolonc.2025.04.011_bib0099","article-title":"Sertoli-Leydig cell tumor with DICER1 mutation","volume":"52","author":"Jansen","year":"2024","journal-title":"Gynecol Oncol Rep"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:28:29Z","timestamp":1757338109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392500170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":99,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S107814392500170X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic profiling of urological malignancies using tissue-based next generation sequencing","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}